Read & Download your Issue of Wednesday – February  10 FNN News

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

• The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection against the newer variants B.1.1.7 (85.6%) and B.1.351 (60%), preliminary data from clinical trials show.
• Interim results have been released from a phase III trial carried out in the UK with more than 15 000 participants aged between 18 and 84, including 27% over the age of 65.

Source: BMJ

Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows

• The Pfizer and BioNTech covid-19 vaccine may provide some early protection, starting 12 days after the first dose, the peer reviewed results of a phase III trial have found.
• The study, published in the New England Journal of Medicine,1 found that vaccine efficacy between the first and second doses was 52% (95% credible interval 29.5% to 68.4%), with 39 cases of covid-19 in the vaccine group and 82 cases in the placebo group.
• Seven or more days after the second dose, vaccine efficacy then rose to 95% (90.3% to 97.6%), with eight covid-19 cases reported in the vaccine group and 162 cases in the placebo group.

Source: The BMJ

Covid-19: WHO warns against “vaccine nationalism” or face further virus mutations

• World Health Organization officials have voiced concerns at “vaccine nationalism” which could increase the risk of the coronavirus mutating further, after a week long row over a shortfall in EU supplies of covid-19 vaccines.
• Bruce Aylward, senior adviser to WHO’s director general, said, “Anything that restricts the ability to get these products out will affect our ability to control this disease and prevent variants emerging. The world is going to have to collaborate to get out of this,”
• Tedros Adhanom Ghebreyesus called on countries that had vaccines left over after vaccinating their own priority health staff and at-risk groups to share them with others under the Covax programme.

Source: The BMJ

COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options

• The 2019 novel coronavirus (COVID-19) has quickly become one of the most dire international pandemic crises since the 1918 Spanish flu.
• Evidence for COVID-19 pharmacological therapies has shown rapid growth and a diverse array of results, but an assessment of the value of each piece of evidence must be reinforced.
• This article aims to review utilized therapies, the evidence level supporting these therapies, as well as drugs under investigation for the treatment of COVID-19.

Source: Springer Link

Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19

• Evidence suggests the role of an inflammatory storm in COVID-19 complications.
• Colchicine is an orally administered, anti-inflammatory medication beneficial in gout, pericarditis and coronary disease.
• They performed a randomized, double-blind trial involving non-hospitalized patients with COVID-19 diagnosed by polymerase chain reaction (PCR) testing or clinical criteria.
• The patients were randomly assigned to receive colchicine (0.5 mg twice daily for 3 days and once daily thereafter) or placebo for 30 days.
• Among non-hospitalized patients with COVID-19, colchicine reduces the composite rate of death or hospitalization.

Source: MedRxiv

The value of healthcare worker support strategies to enhance wellbeing and optimise patient care

• The World Health Organization has recognised the impact of the SARS-CoV-2 pandemic on healthcare worker (HCW) mental health and wellbeing.
• Anticipating these effects locally, they developed strategies to support the healthcare team team, to equip them to care for themselves as well as patients.
• A strategy to support HCW teams during a crisis is vital to enhance wellbeing.
• Interventions implemented, have supported the provision of high-quality patient care, innovation and research throughout the pandemic.

Source: Royal College of Pysicians

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Clinical Research E-News ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Clinical Research FNN E-News, for a publication of News

Read & Download FNN Issue 8 of April 2020 FNN News